{
    "ticker": "IROHW",
    "name": "Ironwood Pharmaceuticals, Inc.",
    "description": "Ironwood Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for gastrointestinal (GI) diseases. Founded in 1998 and headquartered in Cambridge, Massachusetts, Ironwood is dedicated to addressing significant unmet medical needs in the GI space. The company's flagship product, LINZESS (linaclotide), is a once-daily prescription medication approved for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Ironwood collaborates with major pharmaceutical companies to enhance the reach and effectiveness of its product portfolio, aiming to improve the quality of life for patients suffering from debilitating GI conditions. With a strong emphasis on research and development, Ironwood is committed to advancing new therapeutics that address various GI disorders, leveraging its expertise in drug development and patient care. The company\u2019s mission centers around transforming GI treatment options through science and innovation, while maintaining a patient-first approach in all its initiatives.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Cambridge, Massachusetts, USA",
    "founded": "1998",
    "website": "https://www.ironwoodpharma.com",
    "ceo": "Mark Mallon",
    "social_media": {
        "twitter": "https://twitter.com/IronwoodPharma",
        "linkedin": "https://www.linkedin.com/company/ironwood-pharmaceuticals/"
    },
    "investor_relations": "https://ir.ironwoodpharma.com",
    "key_executives": [
        {
            "name": "Mark Mallon",
            "position": "CEO"
        },
        {
            "name": "Michael A. McCarthy",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Gastrointestinal Therapies",
            "products": [
                "LINZESS"
            ]
        }
    ],
    "seo": {
        "meta_title": "Ironwood Pharmaceuticals, Inc. | Innovative Gastrointestinal Therapies",
        "meta_description": "Explore Ironwood Pharmaceuticals, Inc., a leader in gastrointestinal therapies. Discover LINZESS and our commitment to transforming GI treatment options.",
        "keywords": [
            "Ironwood Pharmaceuticals",
            "LINZESS",
            "Gastrointestinal Disorders",
            "IBS",
            "Chronic Constipation",
            "Biotechnology"
        ]
    },
    "faq": [
        {
            "question": "What is Ironwood Pharmaceuticals known for?",
            "answer": "Ironwood Pharmaceuticals is known for its innovative therapies for gastrointestinal diseases, particularly LINZESS."
        },
        {
            "question": "Who is the CEO of Ironwood Pharmaceuticals?",
            "answer": "Mark Mallon is the CEO of Ironwood Pharmaceuticals, Inc."
        },
        {
            "question": "Where is Ironwood Pharmaceuticals headquartered?",
            "answer": "Ironwood Pharmaceuticals is headquartered in Cambridge, Massachusetts, USA."
        },
        {
            "question": "What is LINZESS used for?",
            "answer": "LINZESS is used for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC)."
        },
        {
            "question": "When was Ironwood Pharmaceuticals founded?",
            "answer": "Ironwood Pharmaceuticals was founded in 1998."
        }
    ],
    "competitors": [
        "AMGN",
        "BMY",
        "GILD",
        "JAZZ"
    ],
    "related_stocks": [
        "VRTX",
        "ABBV",
        "PFE",
        "MRNA"
    ]
}